AU4425397A - Antisense gene therapy for rna viruses - Google Patents

Antisense gene therapy for rna viruses

Info

Publication number
AU4425397A
AU4425397A AU44253/97A AU4425397A AU4425397A AU 4425397 A AU4425397 A AU 4425397A AU 44253/97 A AU44253/97 A AU 44253/97A AU 4425397 A AU4425397 A AU 4425397A AU 4425397 A AU4425397 A AU 4425397A
Authority
AU
Australia
Prior art keywords
gene therapy
rna viruses
antisense gene
antisense
viruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU44253/97A
Inventor
Jack M. Bernstein
Arlene Stecenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wright State University
Vanderbilt University
Original Assignee
Wright State University
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wright State University, Vanderbilt University filed Critical Wright State University
Publication of AU4425397A publication Critical patent/AU4425397A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU44253/97A 1996-09-18 1997-09-18 Antisense gene therapy for rna viruses Abandoned AU4425397A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2628596P 1996-09-18 1996-09-18
US60026285 1996-09-18
PCT/US1997/016628 WO1998012312A1 (en) 1996-09-18 1997-09-18 Antisense gene therapy for rna viruses

Publications (1)

Publication Number Publication Date
AU4425397A true AU4425397A (en) 1998-04-14

Family

ID=21830947

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44253/97A Abandoned AU4425397A (en) 1996-09-18 1997-09-18 Antisense gene therapy for rna viruses

Country Status (2)

Country Link
AU (1) AU4425397A (en)
WO (1) WO1998012312A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828105B2 (en) * 2001-10-16 2004-12-07 Avi Biopharma, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US7507809B2 (en) 2005-01-07 2009-03-24 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV and therapeutic uses thereof
EP1937278B1 (en) 2005-09-08 2012-07-25 AVI BioPharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
WO2007030691A2 (en) 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8785407B2 (en) 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US8697858B2 (en) 2009-11-13 2014-04-15 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection

Also Published As

Publication number Publication date
WO1998012312A1 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
AU2946295A (en) Targeted gene delivery system
AU4787697A (en) Therapeutic gene
AU9023798A (en) Mdm2-specific antisense oligonucleotides
AU6535096A (en) Methods and means for targeted gene delivery
AU3737297A (en) Bacteriophage-mediated gene therapy
AU3206697A (en) Ribozyme-mediated gene replacement
AU2317095A (en) Dna sequences
AU5259498A (en) Antisense oligonucleotides
HUP0104046A3 (en) Adenovirus-mediated gene therapy
PL345207A1 (en) Gene therapy method
AU4425397A (en) Antisense gene therapy for rna viruses
AU7165498A (en) Methods for treating viral infections
AU4212897A (en) Method of preparing plasmid DNA
AU7729498A (en) Methods and uses for transposon-based gene targeting
AU2051297A (en) Gene therapy method using fgf-5
AU2585197A (en) Antisense approach to gene inhibition
AU4173497A (en) Monocot seed gene expression system
AU6060999A (en) Gene replacement therapy for muscular dystrophy
AU2750197A (en) Dna replication-regulating genes
AU6168294A (en) Triplex-forming paired-ion oligonucleotides and methods for preparing and using same
AU2801497A (en) Oligonucleotides with anti-epstein-barr virus activity
AU7364998A (en) Antisense oligonucleotides specific for thymidylate synthase
AU4552700A (en) Gene therapy
AU3730695A (en) Human checkpoint gene and gene for antisense RNA thereof
AU2944697A (en) Modified small rna viruses